ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2011
[Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy].
Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Clinical application of nano-carbon to improve the accuracy of lymph node staging in patients with advanced gastric cancer receiving neoadjuvant chemotherapy: a prospective randomized controlled trial.Journal of gastrointestinal oncology · 2021Article
- [Palliative surgery in visceral medicine. Exemplified by colorectal and gastric cancer].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2016Observational
- [Palliative treatment of advanced gastric cancer from surgical point of view].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2015Observational
- Positron Emission Tomography (PET) in Oncology.Cancers · 2014Review
- [Comparison of recurrence patterns in esophageal carcinoma after surgery alone and surgery after neoadjuvant chemoradiotherapy: a secondary analysis of the CROSS study].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Article
- Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.European journal of nuclear medicine and molecular imaging · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the current European and German S3 guidelines, neoadjuvant chemotherapy is now an integral part of the treatment of locally advanced gastric cancer and adenocarcinoma of the esophagogastric junction. Neoadjuvant therapy seeks to achieve downsizing of the primary tumor, lowering of the T and N categories and eradication of micrometastases. As the indications for neoadjuvant treatment are based on pretherapeutic information alone, a sophisticated clinical staging plays a central role. Despite all progress made in the field of diagnostic work-up, clinical staging often fails. Despite this fact, controlled randomized trials showed that neoadjuvant chemotherapy enhances the rate of curative (R0) resections and reduces the likelihood of systemic relapse. Overall, survival can be improved by neoadjuvant chemotherapy. The current research is focused on the molecular prediction of response and early response monitoring with functional imaging. New targeted drugs are being integrated into the peri-operative treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.